EUVIMEDEUVIMED entdecken
Crossref

Impact of pre‐transplant donor specific antibodies detected by Luminex with negative microlymphocytotoxicity assay and flow crossmatch in live‐related renal transplant recipients

Khawar Abbas iD, Tahir Aziz iD, Wajiha Musharaf iD, Muhammed Mubarak iD, Mirza Naqi Zafar iD

Clinical Transplantation · 2023

DOI: 10.1111/ctr.14935 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Transplantation, 2023. Verfasst von Khawar Abbas und 4 weiteren Autor:innen. Beteiligte Einrichtung: Immunology Department, SIUT, Karachi, Pakistan. Hauptthemen laut MEDLINE: Kidney Transplantation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction/Aim The Luminex assay, where beads are coated with a single HLA antigen, has been shown to detect HLA antibodies with more sensitivity and specificity as compared to microlymphocytotoxicity (CDC) assay and flow cross match (FCXM). We report the impact of low Mean Flourescence intensity (MFI) pre‐transplant DSA by Luminex with negative CDC and FCXM on acute rejection, graft function, and survival.

Methods

In this retrospective study between January 2015 to December 2021, 45 recipients had pre‐transplant anti‐HLA donor‐specific antibodies (DSAs) detected by Luminex. Two control groups of 45 patients each matched for age and gender, first with non‐DSA HLA antibodies and second with no antibodies by Luminex were selected to compare outcomes with DSA group.

Results

In the DSA group of 45, 22 (48.8%) had class I (MFI mean 4043 ± 1909, range: 1096–7111), 20 (44.4%) class II (MFI mean 3601 ± 2310, range: 1031–9259), and 3 (6.6%) both class I (MFI mean 4746 ± 1922) and class II (MFI mean 3940 ± 2312) antibodies. Acute rejection episodes were reported in 15.6%, DSA group, 17.8% in non‐DSA, and 24.4% in no antibody group ( p = .538). Death censored graft survival at 1 and 5 years was 98% and 93% in DSA group, 100% and 95% in non‐DSA and 93% and 85% in the no antibody group ( p = .254).

Conclusions

Patients with low MFI DSA pre‐transplant, with a negative CDC and FCXM under ATG induction, have similar graft outcomes at 1 and 5 years when compared to non‐DSA and no antibody groups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationHumansRetrospective StudiesAntibodiesTissue DonorsTransplant RecipientsAntilymphocyte SerumGraft SurvivalGraft RejectionHLA AntigensHistocompatibility TestingIsoantibodies

Stichwörter der Autor:innen

DSALuminexgraft outcomeskidney transplantpre-transplant

Substanzen

AntibodiesAntilymphocyte SerumHLA AntigensIsoantibodies

Autor:innen und Institutionen

  • Immunology Department, SIUT, Karachi, Pakistan.
  • Transplantation Department, SIUT, Karachi, Pakistan.
  • Histopathology Department, SIUT, Karachi, Pakistan.
  • Pathology Department, SIUT, Karachi, Pakistan.

ORCID-Profile: Khawar Abbas, Tahir Aziz, Wajiha Musharaf, Muhammed Mubarak, Mirza Naqi Zafar

Zitieren

APA

Abbas, K., Aziz, T., Musharaf, W., Mubarak, M., & Zafar, M. N. (2023). Impact of pre‐transplant donor specific antibodies detected by Luminex with negative microlymphocytotoxicity assay and flow crossmatch in live‐related renal transplant recipients. Clinical Transplantation. https://doi.org/10.1111/ctr.14935

Vancouver

Abbas K, Aziz T, Musharaf W, Mubarak M, Zafar MN. Impact of pre‐transplant donor specific antibodies detected by Luminex with negative microlymphocytotoxicity assay and flow crossmatch in live‐related renal transplant recipients. Clinical Transplantation. 2023. doi:10.1111/ctr.14935

BibTeX
@article{Abbas2023,
  author = {Abbas, Khawar and Aziz, Tahir and Musharaf, Wajiha and Mubarak, Muhammed and Zafar, Mirza Naqi},
  title = {Impact of pre‐transplant donor specific antibodies detected by Luminex with negative microlymphocytotoxicity assay and flow crossmatch in live‐related renal transplant recipients},
  journal = {Clinical Transplantation},
  year = {2023},
  doi = {10.1111/ctr.14935}
}
Kostenlos starten →